Jaguar Health (JAGX) and Napo Therapeutics announced that the first short bowel syndrome with intestinal failure patient has been dosed in the independent investigator-initiated pediatric POC trial of crofelemer, Jaguar’s novel plant-based antidiarrheal prescription drug. The first infant with microvillus inclusion disease was dosed as part of the same IIT two weeks ago. POC data generated from this study potentially in the first half of 2025 could lead to reimbursed early patient access to crofelemer for these indications in certain European countries. The trial is being conducted by Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology who is the Division Chief of the Pediatric Gastroenterology, Hepatology & Nutrition Division at Sheikh Khalifa Medical City, a flagship tertiary hospital in the UAE and the largest teaching medical center in Abu Dhabi.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar supports evauation of FDA-approved crofelemer for GI issues from GLP-1
- Jaguar Health announces first patient dosed in IIT evaluating crofelemer
- Jaguar Health announces import of coca leaf by Magdalena Biosciences JV
- Jaguar Health’s Napo initiates Phase 2 study to evaluate crofelemer for MVID
- Jaguar Health participates in a conference call with Ladenburg Thalmann